CN115605586B - 工程化溶瘤腺病毒 - Google Patents

工程化溶瘤腺病毒 Download PDF

Info

Publication number
CN115605586B
CN115605586B CN202180026103.3A CN202180026103A CN115605586B CN 115605586 B CN115605586 B CN 115605586B CN 202180026103 A CN202180026103 A CN 202180026103A CN 115605586 B CN115605586 B CN 115605586B
Authority
CN
China
Prior art keywords
gene
virus
modified virus
e3gp19k
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180026103.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN115605586A (zh
Inventor
袁明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Huayao Kangming Biopharmaceutical Co ltd
Original Assignee
Shenzhen Huayao Kangming Biopharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Huayao Kangming Biopharmaceutical Co ltd filed Critical Shenzhen Huayao Kangming Biopharmaceutical Co ltd
Publication of CN115605586A publication Critical patent/CN115605586A/zh
Application granted granted Critical
Publication of CN115605586B publication Critical patent/CN115605586B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202180026103.3A 2020-04-07 2021-04-07 工程化溶瘤腺病毒 Active CN115605586B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063006115P 2020-04-07 2020-04-07
US63/006,115 2020-04-07
PCT/IB2021/052898 WO2021205364A1 (en) 2020-04-07 2021-04-07 Engineered oncolytic adenovirus

Publications (2)

Publication Number Publication Date
CN115605586A CN115605586A (zh) 2023-01-13
CN115605586B true CN115605586B (zh) 2024-09-06

Family

ID=78022983

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180026103.3A Active CN115605586B (zh) 2020-04-07 2021-04-07 工程化溶瘤腺病毒

Country Status (5)

Country Link
US (1) US20230149485A1 (https=)
EP (1) EP4133061A4 (https=)
JP (1) JP7758355B2 (https=)
CN (1) CN115605586B (https=)
WO (1) WO2021205364A1 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102174479B (zh) * 2011-03-02 2013-04-03 北京锤特生物科技有限公司 靶向性治疗人肿瘤的溶肿瘤腺病毒及其应用
DK2986311T3 (en) * 2013-04-18 2019-02-25 Tilt Biotherapeutics Oy IMPROVED ADOPTIVE CELL THERAPY
GB201802539D0 (en) * 2018-02-16 2018-04-04 Univ College Cardiff Consultants Ltd Modified adenoviruses
GB201804468D0 (en) * 2018-03-21 2018-05-02 Valo Therapeutics Oy PeptiCRAd Cancer Therapy
JP2021527694A (ja) * 2018-06-21 2021-10-14 レプリミュン リミテッド 腫瘍溶解性ウイルスを用いた処置
CN110218707B (zh) * 2019-05-29 2021-10-22 上海市公共卫生临床中心 一种新型溶瘤病毒及其制备方法和应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
denovirus‐mediated interleukin 21 gene transfer enhances antitumor immunity and reduces tumorigenicity of Hepa1‐6 in mice;Jiyu Ju等;Oncology Letters;第12卷(第5期);第3749-3754页，尤其是摘要 *
Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent;Pengju Wang等;Nature communications;第8卷;第1-15页，尤其是第2页第1、4段、图1a、图4a *
The Novel Oncolytic Adenoviral Mutant Ad5-3D-A20T Retargeted to avb6 Integrins Efficiently Eliminates Pancreatic Cancer Cells;Y. K. Stella Man等;Models and Technologies;第17卷(第2期);第575–587页，尤其是第576页第3、6段，图5，摘要 *

Also Published As

Publication number Publication date
JP2023521076A (ja) 2023-05-23
US20230149485A1 (en) 2023-05-18
EP4133061A4 (en) 2024-05-29
JP7758355B2 (ja) 2025-10-22
WO2021205364A1 (en) 2021-10-14
EP4133061A1 (en) 2023-02-15
CN115605586A (zh) 2023-01-13

Similar Documents

Publication Publication Date Title
JP7159304B2 (ja) 腫瘍および／または癌の処置のための医薬のための単離された組換え体腫瘍溶解性アデノウイルス、医薬組成物、およびそれらの使用
CN109554353B (zh) 分离的重组溶瘤痘病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途
US12357672B2 (en) Protein molecule of interleukins 12a and b combined with additional factors
JP2021527694A (ja) 腫瘍溶解性ウイルスを用いた処置
JPH09501837A (ja) 遺伝子治療のための単球−マクロファージ細胞株に由来する組換え細胞
CN105307671A (zh) 增强过继细胞疗法
CN108307642B (zh) 改造的白介素12及其在制备治疗肿瘤药物中的用途
US20240180983A1 (en) Adenovirus encoding il-15
CA3048185A1 (en) Armed replication-competent oncolytic adenoviruses
JP7420751B2 (ja) Ｉ型インターフェロン及びｃｄ４０－配位子を用いる腫瘍溶解性ウイルス又は抗原提示細胞媒介性癌治療
JP2015506697A (ja) １２量体ｔｒａｉｌ及びｈｓｖ−ｔｋ自殺遺伝子を同時に発現するベクター並びにそれを用いた抗癌幹細胞治療剤
CN114592010A (zh) NK-CAR-MbIL-15细胞及其制备方法和应用
JP5042826B2 (ja) 腫瘍壊死因子関連アポトーシス誘導リガンド（ｔｒａｉｌ）を産生するように遺伝子操作された腫瘍帰巣細胞
KR102768669B1 (ko) 종양 치료용 콕삭키바이러스 b
CN117402261B (zh) 一种基于重组腺病毒的car-nk细胞制备方法及其应用
CN115605586B (zh) 工程化溶瘤腺病毒
Scholl et al. Gene therapy applications to cancer treatment
CN113891747A (zh) 诱导免疫细胞活性的组合物及使用该组合物治疗疾病的方法
CN119925587A (zh) 一种仿生个性化原位肿瘤疫苗及其制备与使用方法
WO2025031347A1 (zh) 肿瘤疫苗及其用途
CN120789239A (zh) 重组溶瘤病毒和单克隆抗体联用在制备用于治疗hbv阳性肝癌的药物中的应用
HK40054249A (en) Oncolytic virus or antigen presenting cell mediated cancer therapy using type i interferon and cd40-ligand
CN120796204A (zh) 一种免疫激活型重组溶瘤病毒及其应用
HK40004557A (en) Isolated recombinant oncolytic poxvirus, pharmaceutical composition, and use thereof in treatment of tumors and/or cancer
HK40054249B (zh) 使用i型干扰素和cd40配体的溶瘤病毒或抗原呈递细胞介导的癌症治疗

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant